Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1

Arthritis Rheum. 1994 Jul;37(7):992-9. doi: 10.1002/art.1780370703.


Objective: To assess the safety and efficacy of a monoclonal antibody (MAb) to intercellular adhesion molecule 1 (ICAM-1; CD54) in rheumatoid arthritis (RA).

Methods: A phase I/II, open-label, dose-escalation study of 32 patients.

Results: During treatment, a peripheral CD3+/CD4+ lymphocytosis was noted, and several patients demonstrated transient cutaneous anergy, which suggests that therapy modified T cell recirculation. Thirteen of the 23 patients who received 5 days of treatment demonstrated clinical improvement through day 29, and 9 of 23 through day 60. Adverse effects were minor and transient.

Conclusion: Anti-ICAM-1 MAb therapy was well tolerated, resulted in a transient alteration in T lymphocyte recirculation, and effected clinical improvement in some RA patients.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Antibodies, Monoclonal / therapeutic use*
  • Antigens, CD / immunology
  • Arthritis, Rheumatoid / drug therapy*
  • Cell Adhesion Molecules / immunology*
  • Cell Count
  • Female
  • Humans
  • Hypersensitivity, Delayed / diagnosis
  • Intercellular Adhesion Molecule-1
  • Lymphocyte Subsets
  • Lymphocytes
  • Male
  • Middle Aged
  • Monocytes
  • Neutrophils
  • Phenotype


  • Antibodies, Monoclonal
  • Antigens, CD
  • Cell Adhesion Molecules
  • Intercellular Adhesion Molecule-1